サポートされていないブラウザが使用されています。
このサイトの一部の機能が正しく機能しない可能性があります。最適なユーザーエクスペリエンスを得るために、このサイトはChrome、Firefox、Safari、またはEdgeで表示してください。

Solutions for pDNA / mRNA Manufacturing

プラスミドDNAは、mRNAや、レンチウイルスベクター、アデノ随伴ウイルス(AAV)ベクターなどウイルスベクターを生産するための出発原料として広く採用されています。

mRNA (2).png

ACCELERATING pDNA / mRNA MANUFACTURING

End-to-end manufacturing solutions

With the proven success of mRNA-based vaccines in addressing the Covid-19 pandemic, mRNA technology is at the forefront of transforming the world of medicine, and the biopharma industry has ongoing clinical trials to develop both vaccines and therapies to treat infectious diseases and even cancer. pDNA is a critical raw material and acts as a template for mRNA manufacturing. Although cell-free, the IVT mRNA process workflow is impacted by low process yields and scalability challenges. Repligen technologies are uniquely suited to help overcome these challenges in process development and manufacturing at the commercial scale for pDNA and mRNA.

課題
ソリューション

Global high demand

  • Scalability and cost effectiveness
  • Accelerate speed to market
  • Shear sensitivity
  • Low productivity and purification yield

Increased pDNA and mRNA yield
Optimized vector production

  • pDNA: Intensify microbial growth for pDNA production with perfusion-based technology
  • Simplify manufacturing process by replacing centrifugation with microfiltration TFF
  • On-line pDNA product purity monitoring (Process Analytical Technology)

Fully scalable Chromatography and TFF equipment designed for low shear and low hold-up volume performance, maximizing product purity and recovery

Product quality 
Product quality and purity

  • pDNA: open circular pDNA removal
  • mRNA: removal of rDNA, dsRNA, RNA fragments,
    non-encapsulated LNPs

Increased pDNA and mRNA quality

  • Fully sterile and closed automated systems with single-use flow paths
  • Pre-packed columns enable purification and process consistency
  • Analytical in-line technology 

Limited process knowledge

  • Limited scale-up process and implementation experience
  • Lack of in-line process monitoring for cell and cellfree platforms

Expert consultation
Hands-on process and implementation approach from recognized Gene Therapy, oncolytic and vaccines industry experts

 

pDNA/mRNA MANUFACTURING TECHNOLOGIES

XCell_SU_2-6-10.jpg

XCell ATF® Systems

  • Scalable, single-use cell retention
  • Higher viable cell density and total pDNA titer

KrosFlo_Label-Repligen-Blue.png

中空糸フィルター

  • Wide range of membrane formats, chemistries and pore sizes
  • Recommended MWCO for TFF1: 10-300 kDa

SIUSgamma_Front.jpg

SIUS® Gamma Flat Sheet Cassettes

  • Fully assembled, irradiated cassettes for high flux performance and reduced process time
  • Recommended MWCO: 10-300 kDa

TFF 050 With 50L tulip Front.png

KrosFlo® TFFシステム

  • Automated hollow fiber or flat sheet TFF
  • Ideal for shear-sensitive vectors with low hold-up volume

opus_GT.jpg

OPUS® Pre-packed Columns

  • Broad range covering process development and commercial manufacturing requirements
  • Pack any resin for plasmid and mRNA purification

Chrome 25 November2021 alt 1 (4).png

KRM™ Chromatography Systems

  • Superior gradient control, higher peak resolution, high yield
  • Ready-to-operate single-use flow path

FlowVPX_Clean_w-Stand_Capped_w-Shadow.png

FlowVPX® Device

  • In-line PAT monitoring in downstream
  • Applications in pDNA, mRNA and LNP manufacturing

small_valves.jpg

ご紹介

  • State-of-the-art valve and tubing technology
  • Designed-for-purpose transfer and containment assemblies

ProConnex-TFDF-6000-Flow-Path.png

ProConnex®フローパス

  • Single-use, sterile, configurable flow paths
  • Plug and play fluid management

Repligen technical support Ensures success

遺伝子治療に関する専門知識を有するRepligenのフィールドアプリケーションスペシャリスト(FAS)は、相談から実施までのサポートをグローバルに提供しています。

コンサルティング

  • 理論
  • 技術的適合
  • 実験計画

評価

  • デモ
  • トレーニング
  • データ分析

開発

  • Optimization
  • フローパスのサイジング
  • システムのサイジング

導入

  • 拡大
  • 検証
  • 長期のトレーニング計画

リソース

すべて展開

TFDF®テクノロジーを利用してレンチウイルスベクター生産プロセスを強化する
Thomas Williams、Oliver Goodyear、Lee Davies、Carol Knevelman、Michael Bransby、Kyriacos Mitrophanous、James Miskin
Cell and Gene Therapy Insights、2020年4月

Gene Therapy Manufacturing
by René Gantier, PhD, Director of Gene Therapy Technologies, Repligen Corporation 

Repligen Corporation
April 2021

クローズドの、照射済みシングルユースフラットシートTFFデバイスを展開するAAV研究
by David Bianchi, Carl Breuning, Michael LaBreck, Shelly Parra, Mary Jo Wojtusik, Repligen Corporation 
Alex Meola, Michael Mercaldi, Thomas Thiers, Homology, Medicines Inc. 

Repligen Corporation
Homology, Medicines社
2020年7月